CN1231762C - 对候选化合物进行直接鉴定的方法 - Google Patents

对候选化合物进行直接鉴定的方法 Download PDF

Info

Publication number
CN1231762C
CN1231762C CNB998122653A CN99812265A CN1231762C CN 1231762 C CN1231762 C CN 1231762C CN B998122653 A CNB998122653 A CN B998122653A CN 99812265 A CN99812265 A CN 99812265A CN 1231762 C CN1231762 C CN 1231762C
Authority
CN
China
Prior art keywords
receptor
seq
receptors
protein
gpr6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998122653A
Other languages
English (en)
Chinese (zh)
Other versions
CN1323396A (zh
Inventor
多米尼克·P·比汉
德里克·T·查默斯
廖王蓁
林伊玲
凯文·洛斯
陈若平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN1323396A publication Critical patent/CN1323396A/zh
Application granted granted Critical
Publication of CN1231762C publication Critical patent/CN1231762C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
CNB998122653A 1998-07-31 1999-07-30 对候选化合物进行直接鉴定的方法 Expired - Fee Related CN1231762C (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US60/094,879 1998-07-31
US10630098P 1998-10-30 1998-10-30
US60/106,300 1998-10-30
US11090698P 1998-12-04 1998-12-04
US60/110,906 1998-12-04
US12185199P 1999-02-26 1999-02-26
US60/121,851 1999-02-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200510116399 Division CN1847853A (zh) 1998-07-31 1999-07-30 内源组成激活g蛋白偶联孤独受体

Publications (2)

Publication Number Publication Date
CN1323396A CN1323396A (zh) 2001-11-21
CN1231762C true CN1231762C (zh) 2005-12-14

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998122653A Expired - Fee Related CN1231762C (zh) 1998-07-31 1999-07-30 对候选化合物进行直接鉴定的方法

Country Status (13)

Country Link
EP (1) EP1095275B1 (enExample)
JP (1) JP2002521681A (enExample)
CN (1) CN1231762C (enExample)
AT (1) ATE432472T1 (enExample)
AU (1) AU751080B2 (enExample)
CA (1) CA2338543C (enExample)
DE (1) DE69940923D1 (enExample)
DK (1) DK1095275T3 (enExample)
IL (1) IL140858A0 (enExample)
MX (1) MXPA01001176A (enExample)
NO (1) NO20010509L (enExample)
NZ (1) NZ509429A (enExample)
WO (1) WO2000006597A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU2001249885A1 (en) 2000-04-07 2001-10-23 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
AU2003219030A1 (en) * 2002-03-22 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
AU2003266238A1 (en) * 2002-08-05 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
AU2003291967A1 (en) * 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220715C (en) * 1995-06-07 2004-11-02 Praecis Pharmaceuticals Incorporated Functional bioassay for g-protein coupled receptor agonists and antagonists
WO1997011159A1 (en) * 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
AU743259B2 (en) * 1997-04-14 2002-01-24 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Also Published As

Publication number Publication date
DE69940923D1 (de) 2009-07-09
MXPA01001176A (es) 2005-07-25
IL140858A0 (en) 2002-02-10
ATE432472T1 (de) 2009-06-15
CA2338543A1 (en) 2000-02-10
AU751080B2 (en) 2002-08-08
EP1095275B1 (en) 2009-05-27
NO20010509L (no) 2001-03-19
WO2000006597A2 (en) 2000-02-10
NO20010509D0 (no) 2001-01-30
DK1095275T3 (da) 2009-09-28
EP1095275A2 (en) 2001-05-02
WO2000006597A9 (en) 2000-07-13
NZ509429A (en) 2002-06-28
JP2002521681A (ja) 2002-07-16
CN1323396A (zh) 2001-11-21
WO2000006597A3 (en) 2000-05-18
CA2338543C (en) 2009-12-29
AU5545999A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
CN1310945C (zh) 人g蛋白偶联受体的内源形式和非内源形式
CN1154494C (zh) 腺苷a3受体调节剂
CN1146566C (zh) 2-芳基-8-氧代二氢嘌呤衍生物及其制备方法、含该衍生物的药物组合物、及其中间体
CN1186326C (zh) 丙－1,3－二酮衍生物
CN1167420C (zh) 用于调制丝氨酸/苏氨酸蛋白激酶功能的氮杂苯并咪唑类化合物
CN1324405A (zh) 新型g蛋白偶联型受体蛋白、dna及其配体
CN1516706A (zh) 人g蛋白偶联受体的内源性和非内源性形式
CN1411448A (zh) 调节人5－羟色胺受体的吡唑衍生物
CN1751038A (zh) 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
CN1660815A (zh) 环胺衍生物及其作为药物的用途
CN1091469A (zh) Ptp 1d：一种新蛋白质酪氨酸磷酸
CN1155402C (zh) 一种抑制信号－传导蛋白和glgf(pdz/d hr)区域之间相互作用的化合物及其应用
CN1231762C (zh) 对候选化合物进行直接鉴定的方法
CN1882689A (zh) 产生嗅觉gpcr的方法
CN1549858A (zh) 内源和非内源型人g蛋白偶联受体
CN1165147A (zh) 鸟嘌呤核苷酸结合蛋白偶联受体蛋白质，其生产和应用
CN1341123A (zh) 新型g蛋白偶联型受体蛋白及其dna
CN1744910A (zh) 含有半乳凝素9的医药
CN1333786A (zh) 新的g蛋白偶联型受体蛋白、其dna及其配体
CN1617737A (zh) 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
CN1364167A (zh) G蛋白偶联受体6的小分子调节剂
CN101076331A (zh) 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
CN1397019A (zh) 筛选方法
CN1499970A (zh) Gal3受体拮抗剂在治疗抑郁和/或焦虑中的应用及在这种方法中有用的化合物
CN1720046A (zh) 作为抗脂解药用于治疗血脂异常等代谢相关疾病的5－取代的2h－吡唑－3－甲酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051214

Termination date: 20120730